Introduction
Total intravenous anaesthesia (TIVA) is gaining popularity among paediatric anaesthesia practitioners because propofol and short-acting opioids allow rapid onset and offset of action, reduce postoperative nausea and vomiting, reduce emergence delirium, lessen exposure to atmospheric pollutants and can be used in peripheral locations without the need for a cumbersome anaesthesia machine. It may be the more appropriate technique in patients susceptible to malignant hyperthermia, in scoliosis surgery with neuronal monitoring or in patients with neuromuscular disorders. Advanced concepts in pharmacokinetic modelling and computer technology have led to sophisticated delivery systems that facilitate anaesthesia given by the intravenous route. Depth of anaesthesia monitoring is becoming a standard of care for some adult anaesthetics and validates intravenous techniques [1] . The measurement of expired propofol may soon be possible to guide administration [2 ,3 ] .
TIVA is more demanding of the anaesthetist and despite advances the vast majority of paediatric general anaesthetics remain rooted with inhalational techniques [4 ] . Sevoflurane use for anaesthetic induction avoids venepuncture and pain on injection. Target controlled infusion (TCI) devices are more cumbersome to use than a vaporizer, multiple pumps may be required for a single anaesthetic, pumps vary in characteristics (programming, lag times, pressures generated), and intravenous lines may tissue or become obstructed. Current feedback controls are not rigorous and seldom used in paediatric TIVA. Open-loop rather than closed-loop TCI is the routine in paediatric anaesthesia [5 ,6] .
TCI devices may be directed at either plasma or effect site. These computerized pumps are a considerable advance over earlier manual techniques for adults [7] or children [8, 9] that targeted plasma alone. However, they require input of both pharmacokinetic and pharmacodynamic parameters and a lack of robust pharmacokinetic/ pharmacodynamic estimates limits the use of TCI in children.
Pharmacokinetic parameters
Most TCI techniques use propofol and remifentanil as the principal drugs for induction and maintenance of anaesthesia [10 ] . Popular paediatric programmes used for propofol infusion targeting a plasma concentration are based on data from Marsh et al. [11] and Gepts et al. [12] (Diprifusor), Kataria et al. [9] or Absalom et al. [13] (Paedfusor). Validation studies are few. The Paedfusor, for example, has been validated in only two small studies [13, 14] .
Parameter estimates are different for each dataset (Table 1 ) [15] [16] [17] . Covariate influences such as severity of illness are unaccounted for; the volume in the central compartment, for example, is increased in children after cardiac surgery [17] . Both the administration method (intravenous bolus or infusion) [18] and the collection of venous blood for assay rather than arterial blood will have influence on pharmacokinetic parameter estimates, particularly in the early phase when movement of drug into the effect compartment is occurring. The impact of obesity is debated in the adult literature and unknown in children. Time-concentration profiles and context-sensitive halflives will differ depending on which model is used [19] .
Unfortunately, commonly used datasets [9, [11] [12] [13] 15] have investigated only propofol pharmacokinetics in children out of infancy. Allegaert et al. [20] have attempted to link neonatal data with those from children and extension of those data using allometry and the Hill equation [21 ] suggested a maturation half-time of 44 weeks and a Hill coefficient of 4.9 [22 ] . Clearance is only 10% of the mature value at 28 weeks gestation and 38% at term. A term neonate will achieve 90% of an adult clearance (1.83 l.min À1 .70 kg À1 ) by 30 weeks after term. Although postmenstrual age is the major descriptor of maturation, it is possible that postnatal age may also have an additional effect on maturation of propofol clearance above that predicted by postmenstrual age [23] . Propofol TCI remains unachievable in these lower ages until pharmacokinetics are fully characterized.
Adult remifentanil pharmacokinetic parameters [24] continue to be used in TCI devices for all ages, despite an increasing knowledge about this drug in children [25 ] . There is an element of safety with this approach because both volume of distribution [26] and clearance (expressed as ml/min/kg) [27] decrease with age and because the elimination half-life is small. A larger volume of distribution results in lower peak concentrations after bolus; the higher clearance in children results in lower plasma concentration when infused at adult rates expressed as mg/kg/min. However, remifentanil pharmacokinetics can be described in all age groups by simple application of an allometric model [27] . This standardized clearance of 2790 ml.min À1 .70 kg À1 is similar to that reported by others in children [26, 28] and adults [24, 29] . The smaller the child, the greater the clearance when expressed as ml/min/kg, owing to these enhanced clearance rates; smaller (younger) children will require higher remifentanil infusion rates than larger (older) children and adults to achieve equivalent blood concentrations.
Remifentanil dosage adjustments are required during and after cardiopulmonary bypass owing to marked changes in the volume of distribution of the drug [30 ] . These changes are consistent with adult data where a decrease in metabolism was also noted with temperature reduction [31] and with reports of higher clearance after cardiopulmonary bypass (increased metabolism) than during cardiopulmonary bypass [28] .
Pharmacokinetic interactions between propofol and alfentanil [32] and midazolam [33 ] are reported in adults. Both drugs reduce the metabolic and rapid and slow distribution clearances of propofol. Competition for the CYP3A4 clearance pathway between propofol, midazolam and alfentanil may also affect alfentanil clearance. In addition, a reduction in mean arterial blood pressure is associated with propofol pharmacokinetic alterations that increase the blood propofol concentration [33 ] .
Pharmacodynamic endpoints
Electroencephalogram (EEG)-derived anaesthesia depth monitors (spectral edge frequency, bispectral index, entropy, cerebral state index) can provide an imprecise and drug-dependent measure of arousal [34 ] . Outputs from these monitors can be used as guides for anaesthesia and in so doing have improved outcomes in adults. In older children observations indicate that the performance of the monitors may be similar to that in adults. In infants their use cannot yet be supported in theory or in practice and there remains a need for specific neonate-derived algorithms if EEG-derived anaesthesia depth monitors are to be used for neonates [35 ,36,37 ] or infants [38 ,39 ] .
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The pharmacodynamics of fentanyl and remifentanil in children are similar to those reported in adults. The bispectral index (BIS) showed a close relationship with the modelled effect-site concentration, and, therefore, it may serve as a measure of anaesthetic drug effect in paediatric patients older than 1 year [40 ] . Pharmacodynamic interactions in adults are well described. We might anticipate similar interactions in children. The concomitant use of dexmedetomidine in patients undergoing spinal fusion reduces propofol infusion requirements when compared with those patients receiving only propofol and remifentanil [41 ] . Contrarily, the EC 50 of propofol required to produce adequate anaesthesia for oesophagogastroduodenoscopy in children was unaffected by a concomitant infusion of dexmedetomidine 1 mg/kg given over 10 min [42 ] .
The target concentration desired in the effect site will vary with the effect sought. A propofol concentration of 2-3 mg/l is commonly sought for sedation, whereas 4-6 mg/l is used for anaesthesia. Both the loss and return of consciousness occur at similar target effect-site propofol concentrations (2.0 SD 0.9 mg/l vs. 1.8 SD 0.7 mg/l) in adults [43] and a 'wake-up' concentration of 1.8 mg/l is described in children [44 ] .
Target effect-site remifentanil concentrations commonly used for TIVA also vary. A target of 2-3 mg/l is adequate for laryngoscopy, 6-8 mg/l for laparotomy and 10-12 mg/l might be sought to ablate the stress response associated with cardiac surgery [45 ] . An ED 50 of 3-3.5 mg/kg for intubation is suggested when remifentanil is used in conjunction with propofol 5 mg/kg [46 ] . Older children had a longer duration of apnoea than infants, reflective of increased clearance (ml/min/kg) in infants. Target concentration may also vary with pathology. For example, opioid dosing is commonly reduced in children with cognitive impairment [47 ]; a practice supported by lower BIS scores in this cohort [48 ] .
The link parameter
A single first-order parameter (T 1/2 keo) describes the equilibration half-time between the central and effect compartments. We might anticipate that this delay is size dependent [49] and expect a shorter T 1/2 keo with decreasing age. This has been described for propofol [36] . The concentration in the effect compartment is used to describe the concentration-effect relationship. An accurate estimate of this delay is, therefore, a key issue for controlling depth of anaesthesia in nonsteadystate conditions such as induction, titration to needs during maintenance anaesthesia or recovery [50] . It allows TCI systems to directly target the effect-site concentration and optimize drug delivery by achieving a chosen level of effect as fast as possible without overshoot [50] .
Neither the T 1/2 keo for propofol nor that for remifentanil in children has been described. A commonly used estimate for T 1/2 keo in the adult Marsh model [11] is 2.6 min, although derivation of this value is vague; the adult estimate of 3.4 min from Billard et al. [51] is longer, but it is a lot more than 0.58 min in Struys et al. [52] or 0.43 min in Schnider et al. [18] . Paediatric parameters from the Marsh model [11] have been used to estimate a T 1/2 keo (1.93 min) using the time of maximum effect (Tpeak) methodology [50] . The estimated T 1/2 keo is specific to the pharmacokinetic parameters used and cannot be indiscriminately applied to a different pharmacokinetic parameter set. The model dependence of the T 1/2 keo was demonstrated by an estimate of 1.7 min with the Kataria et al. [9] dataset and 0.8 min with the Paedfusor model [13] . Parameter estimates vary between investigators and predict different time-concentration profiles [19] . In addition, time to peak effect will be dependent on the rate at which drug is infused along with other hypnotic drug interactions and the effect desired [53, 54 ] . Anxiety and catecholamine release may further complicate this measure [54 ] . At a submaximal dose, Tpeak is independent of dose. At supramaximal doses maximal effect will occur earlier than Tpeak and persist for longer duration because of the shape of the sigmoid response curve.
Integrated pharmacokinetic/pharmacodynamic studies in children are lacking, partly because of a lack of consistent effect measures. The use of processed EEG signals may be associated with a delay in signal processing. Clinical endpoints such as the blink reflex or arm movement are crude. The use of incorrect or poorly understood models can result in adverse effects, for example awareness or hypotension. The effect measure used to calculate delay between plasma and effect will also have an impact. BIS recordings in children produced shorter times to peak effect (Tpeak 65 SD 14 s) than those produced by an auditory evoked potential monitor (201 SD 74 s) [55 ].
An incorrect T 1/2 keo will result in an excessive dose in a young child if the effect site is targeted and Tpeak is anticipated to be later than it actually is because it was determined in a teenager or adult (Fig. 1 ). Practices such as targeting the plasma concentration rather than the effect-site concentration may avoid hypotension, but the sophistication of current TCI pumps could allow better control if they were programmed with improved information.
Pharmacokinetic/pharmacodynamic parameter variability
There is considerable variability in any measured plasma concentration when identical doses are given to individuals. Typical values for population pharmacokinetic parameter variability are 10% for tissue distribution, 50% for metabolic elimination and 20% for renal elimination. Variability also exists for pharmacodynamic parameters.
It is possible that the higher incidence of awareness during anaesthesia reported in children [56 ] could be contributed by this between-individual variability. Endoscopic procedures, where TIVA is common, are associated with a higher incidence of awareness than other procedures [57 ] .
Adverse effects
The initial loading dose of remifentanil may cause hypotension, prompting some to target the plasma rather than effect-site concentration. This hypotensive response has been quantified in children undergoing cranioplasty surgery. A steady-state remifentanil concentration of 14 mg/l would typically achieve a 30% decrease in mean arterial blood pressure. The T 1/2 keo of 0.86 min for this haemodynamic effect [58 ] is less than remifentanilinduced spectral edge changes described in adults (T 1/2 keo ¼ 1.34 min) [24, 59 ].
Fentanyl combined with propofol can cause a propranolol-like effect on the sinus node with the potential to enhance cardiac vagal tone [60 ] . Some adverse effects may have therapeutic value. Sinus node and atrioventricular node function are depressed by dexmedetomidine, placing children at risk of bradycardia or atrioventricular nodal block [61 ] . However, dexmedetomidine may have a potential therapeutic role in the acute phase of perioperative atrial and junctional tachyarrhythmias for either heart rate control or conversion to sinus rhythm [62 ] .
Hypotensive effects, reversion to neonatal circulation and reduced clearance causing prolonged sedation in neonates remain stumbling blocks to the use of propofol in neonates [63 ] .
Those other drugs
The pharmacokinetics and pharmacodynamics of ketamine have recently been explored and those estimated parameters could be programmed into infusion devices [64 ,65 ] . Dexmedetomidine pharmacokinetics have been described [66 ] in all ages except premature neonates. The clearance in children after cardiac surgery may be reduced compared with those given dexmedetomidine sedation for radiology [66 ] . Although the target concentration for sedation in intensive care may be similar to adults (0.6 mg/l) [66 ] , a higher target concentration may be required for adequate sedation during radiological procedures [67 ] . Concerns about haemodynamic effects (e.g. bradycardia, hypertension) remain [68 ,69 ] and characterization of these effects may contribute to safer use.
Practical issues
TIVA is harder to implement than inhalational anaesthesia. Children dislike intravenous cannula insertion. Propofol can cause pain on injection. Many anaesthetists will elect to perform a gaseous induction, establish intravenous access and then proceed with TIVA. Steady-state plasma concentrations will take a longer time to achieve without an induction dose [45 ] .
Reliable, large vein, dedicated intravenous access is predicated. One-way valves prevent backflow up intravenous fluid lines. Percutaneous intravenous central catheters (PICC) may be unsatisfactory because high infusion rates are not possible. Combined infusions into a single vein run the risk of inadvertent bolus of a companion drug. Anaesthesia for major surgery may be best served using central venous access, diminishing the risk of undisclosed subcutaneous infusion. The infusion site is not always readily accessible in small children where limbs may be covered in surgical drapes and inadvertent dislodgement, obstruction or subcutaneous tissue infiltration may occur.
Although closed-loop anaesthesia is impractical because effect measures are poor in infants and neonates, changes in cerebral effect measures with changes of dose may at lease confirm that the infusion is not disconnected or subcutaneous. Pump performance characteristics (e.g. lag time), intravenous tubing dead space, and syringe size and type all contribute to the observed response. The more dilute the solution is, the faster the syringe travel with a more matched delivery to change of prescription.
Some pumps display predicted plasma or effect-site concentration from the programmed pharmacokinetic model and are invaluable as an educational tool for demonstrating the intricacies of TIVA. TCI pumps do not have current FDA approval within North America, but it is anticipated that approval will be granted.
Conclusion
There are limitations to the current use of TCI in children. Hardware limitations, a lack of integrated pharmacokinetic/pharmacodynamic analyses, a paucity of data in neonates and infants, and target monitoring issues restrict use. Although intravenous induction remains a hurdle, future drug formulation changes (e.g. watersoluble propofol emulsions or medium chain triglyceride solutions to avoid propofol infusion syndrome), end-tidal breath monitoring, improved anaesthetic depth monitoring, improved pharmacokinetic knowledge and increasing familiarity with technique guarantee continued use for maintenance anaesthesia.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest
Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 434-435). . Propofol can be measured in exhaled gas from the beginning until the end of propofol anaesthesia using gas chromatography mass spectrometry, although there is a time lag between plasma and expired gas concentrations. An ion mobility spectrometer coupled to a multicapillary column for preseparation may be a suitable method to determine propofol concentrations in exhaled air, and may be used to predict propofol concentrations in serum. The authors describe the typical EEG features of adequate general anaesthesia, effects of noxious stimulation, and adjunctive drugs. They stress that any discrepancy must be a stimulus for the immediate critical examination of the patient's state using all the available information rather than reactive therapy to 'treat' a number. During propofol induction in children, the Narcotrend electroencephalogram monitor was capable of following changes in the sedation level of children to some extent, but also had a relatively high probability of incorrectly predicting changes in conscious state. Younger children had higher Narcotrend values than older children at the same level of sedation.
39
Lo SS, Sobol JB, Mallavaram N, et al. Anesthetic-specific electroencephalographic patterns during emergence from sevoflurane and isoflurane in infants and children. Paediatr Anaesth 2009; 19:1157-1165. This is another paper, albeit using inhalation rather than intravenous agents, showing that depth-of-anaesthesia monitors that use algorithms based on the EEGs of adult reference populations may not be appropriate for use in children. The pharmacodynamics of fentanyl and remifentanil in children were similar to those reported in adults. However, the BIS monitor did show a close relationship to the modelled effect-site concentration, and, therefore, it may serve as a measure of anaesthetic drug effect in children older than 1 year of age. The authors also noted age-related changes in propofol T 1/2 keo. Munoz HR, Leon PJ, Fuentes RS, et al. Prospective evaluation of the time to peak effect of propofol to target the effect site in children. Acta Anaesthesiol Scand 2009; 53:883-890. The authors investigated the plasma effect-site equilibration rate constant of propofol determined in children with the use of the time to maximum effect using both BIS and auditory-evoked potentials. This practical investigation shows the small delay between the evolution of Ce of propofol and the BIS and suggests that this can be a useful model to target the effect site in children 3-11 years.
Use of infusion in children is in question
Anderson and Hodkinson 361
